| NAFLD+ | NAFLD- | P-value |
---|---|---|---|
Male, n (%) | 71 (85.54) | 92 (64.79) | < .001* |
Age, yrs | 48.43 ± 8.16 | 48.04 ± 8.84 | .74** |
CDC C, n (%) | 41 (28.87) | 21 (25.30) | .14* |
ALT/AST | 1.46 ± 0.52 | 1.12 ± 0.38 | < .001 ** |
Waist, cm | Â | Â | Â |
Total | 90.26 ± 9.24 | 83.87 ± 9.27 | < .001 ** |
Men | 90.27 ± 8.41 | 85.13 ± 8.42 | < .001 ** |
Women | 90.18 ± 14.00 | 81.57 ± 10.35 | .022 ** |
NRTI Cumulative Exp, months | 124.16 ± 44.86 | 109.85 ± 49.16 | .033 ** |
NNRTI Cumulative Exp, months | 41.94 ± 30.43 | 35.54 ± 30.13 | .15 ** |
PI Cumulative Exp, months | 61.34 ± 36.87 | 60 ± 39.73 | .81 ** |
Hormones | Â | Â | Â |
TSH | 1.93 ± 1.21 | 2.20 ± 1.57 | .19 ** |
T4 | 11.01 ± 1.48 | 10.71 ± 1.38 | .14 ** |
Insulin, median (IQR) | 17.1 (11.65; 22.8) | 10.2 (7.4; 16.5) | < .001§ |
LH, median (IQR) n = 60 | 4.6 (2.8; 9.5) | 6.2 (4; 19.2) | .38§ |
FSH, (IQR) n = 60 | 4 (2.2; 8.9) | 6.3 (4; 20.1) | .21§ |
17-beta-estradiol, (IQR) n = 60 | 81 (27; 104) | 89 (38; 145) | .42§ |
Total testosterone, (IQR) n = 152 | 483 (372; 583) | 433 (343; 531) | .11§ |
Free testosterone, (IQR) n = 152 | 13.2 (9.6; 16.8) | 13 (8.8; 16.3) | .64§ |
GH, (IQR) | .11 (.06; .35) | .28 (.08; 1.04) | .003§ |
IGF1 | 132.32 ± 57.65 | 141.75 ± 61.33 | .26 ** |
IGFBP3, (IQR) | 3210 (2240; 4280) | 3382 (2050; 4297) | .90§ |
Endocrine syndromes | Â | Â | Â |
Hypothyroidism TSH ≥3.5, n (%) | 7 (8.43) | 18 (12.68) | .11* |
Diabetes Fasting glucose ≥126 mg/dL | 20 (24.10) | 17 (11.97) | .018* |
MenopauseLH and FSH > 20 ng/mL and 17 beta-estradiol < 40 pg/mL n = 62 | 2 (16.67) | 7 (14) | .81* |
Hypogonadism testosterone < 200 ng/dL n = 163 | 3 (3.26) | 1 (1.41) | .29* |
Hypopituitarism IGF-1 < 73 pg/mL and IGFBP3 < 1157 pg/mL | 13 (15.66) | 25 (17.61) | .70* |